Combination Niraparib and Dostarlimab Therapy for Recurrent or Persistent Uterine Serous Carcinoma

PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 17, 2023

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions

Recurrent Endometrial Serous Adenocarcinoma

Interventions

PROCEDURE

Biospecimen Collection

Undergo collection of blood samples

PROCEDURE

Computed Tomography

Undergo MRI/CT

BIOLOGICAL

Dostarlimab

Given IV

PROCEDURE

Magnetic Resonance Imaging

Undergo MRI/CT

DRUG

Niraparib

Given PO

Trial Locations (1)

Ohio State University Comprehensive Cancer Center, Columbus

All Listed Sponsors

lead

Casey Cosgrove

OTHER

NCT05870761 - Combination Niraparib and Dostarlimab Therapy for Recurrent or Persistent Uterine Serous Carcinoma | Biotech Hunter | Biotech Hunter